These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27276254)

  • 21. Antiandrogen flutamide protects male mice from androgen-dependent toxicity in three models of spinal bulbar muscular atrophy.
    Renier KJ; Troxell-Smith SM; Johansen JA; Katsuno M; Adachi H; Sobue G; Chua JP; Sun Kim H; Lieberman AP; Breedlove SM; Jordan CL
    Endocrinology; 2014 Jul; 155(7):2624-34. PubMed ID: 24742193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergic prodegradative activity of Bicalutamide and trehalose on the mutant androgen receptor responsible for spinal and bulbar muscular atrophy.
    Giorgetti E; Rusmini P; Crippa V; Cristofani R; Boncoraglio A; Cicardi ME; Galbiati M; Poletti A
    Hum Mol Genet; 2015 Jan; 24(1):64-75. PubMed ID: 25122660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impaired Nuclear Export of Polyglutamine-Expanded Androgen Receptor in Spinal and Bulbar Muscular Atrophy.
    Arnold FJ; Pluciennik A; Merry DE
    Sci Rep; 2019 Jan; 9(1):119. PubMed ID: 30644418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins.
    Saunders HM; Bottomley SP
    Protein Eng Des Sel; 2009 Aug; 22(8):447-51. PubMed ID: 19589877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B2 attenuates polyglutamine-expanded androgen receptor toxicity in cell and fly models of spinal and bulbar muscular atrophy.
    Palazzolo I; Nedelsky NB; Askew CE; Harmison GG; Kasantsev AG; Taylor JP; Fischbeck KH; Pennuto M
    J Neurosci Res; 2010 Aug; 88(10):2207-16. PubMed ID: 20336775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of cis-inhibition of polyQ fibrillation by polyP: PPII oligomers and the hydrophobic effect.
    Darnell GD; Derryberry J; Kurutz JW; Meredith SC
    Biophys J; 2009 Oct; 97(8):2295-305. PubMed ID: 19843462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism.
    Thakur AK; Jayaraman M; Mishra R; Thakur M; Chellgren VM; Byeon IJ; Anjum DH; Kodali R; Creamer TP; Conway JF; Gronenborn AM; Wetzel R
    Nat Struct Mol Biol; 2009 Apr; 16(4):380-9. PubMed ID: 19270701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Expanding Clinical Universe of Polyglutamine Disease.
    Huang S; Zhu S; Li XJ; Li S
    Neuroscientist; 2019 Oct; 25(5):512-520. PubMed ID: 30614396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural and dynamic studies reveal that the Ala-rich region of ataxin-7 initiates α-helix formation of the polyQ tract but suppresses its aggregation.
    Hong JY; Wang DD; Xue W; Yue HW; Yang H; Jiang LL; Wang WN; Hu HY
    Sci Rep; 2019 May; 9(1):7481. PubMed ID: 31097749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disruption of the toxic conformation of the expanded polyglutamine stretch leads to suppression of aggregate formation and cytotoxicity.
    Popiel HA; Nagai Y; Onodera O; Inui T; Fujikake N; Urade Y; Strittmatter WJ; Burke JR; Ichikawa A; Toda T
    Biochem Biophys Res Commun; 2004 May; 317(4):1200-6. PubMed ID: 15094397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spinal and Bulbar Muscular Atrophy Overview.
    Fischbeck KH
    J Mol Neurosci; 2016 Mar; 58(3):317-20. PubMed ID: 26547319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Mechanisms and Therapeutics for SBMA/Kennedy's Disease.
    Arnold FJ; Merry DE
    Neurotherapeutics; 2019 Oct; 16(4):928-947. PubMed ID: 31686397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aggregation and proteasome: the case of elongated polyglutamine aggregation in spinal and bulbar muscular atrophy.
    Rusmini P; Sau D; Crippa V; Palazzolo I; Simonini F; Onesto E; Martini L; Poletti A
    Neurobiol Aging; 2007 Jul; 28(7):1099-111. PubMed ID: 16781019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Towards the treatment of polyglutamine diseases: the modulatory role of protein context.
    Robertson AL; Bottomley SP
    Curr Med Chem; 2010; 17(27):3058-68. PubMed ID: 20629626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A polyglutamine expansion disease protein sequesters PTIP to attenuate DNA repair and increase genomic instability.
    Xiao H; Yu Z; Wu Y; Nan J; Merry DE; Sekiguchi JM; Ferguson DO; Lieberman AP; Dressler GR
    Hum Mol Genet; 2012 Oct; 21(19):4225-36. PubMed ID: 22736030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polyglutamine expansion diseases: More than simple repeats.
    Silva A; de Almeida AV; Macedo-Ribeiro S
    J Struct Biol; 2018 Feb; 201(2):139-154. PubMed ID: 28928079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polyglutamine amyloid core boundaries and flanking domain dynamics in huntingtin fragment fibrils determined by solid-state nuclear magnetic resonance.
    Hoop CL; Lin HK; Kar K; Hou Z; Poirier MA; Wetzel R; van der Wel PC
    Biochemistry; 2014 Oct; 53(42):6653-66. PubMed ID: 25280367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure and Dynamics of the Huntingtin Exon-1 N-Terminus: A Solution NMR Perspective.
    Baias M; Smith PE; Shen K; Joachimiak LA; Żerko S; Koźmiński W; Frydman J; Frydman L
    J Am Chem Soc; 2017 Jan; 139(3):1168-1176. PubMed ID: 28085263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of the Protein Quality Control System in SBMA.
    Rusmini P; Crippa V; Cristofani R; Rinaldi C; Cicardi ME; Galbiati M; Carra S; Malik B; Greensmith L; Poletti A
    J Mol Neurosci; 2016 Mar; 58(3):348-64. PubMed ID: 26572535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and disaggregation of asparagine repeat-containing peptides.
    Lu X; Murphy RM
    J Pept Sci; 2014 Nov; 20(11):860-7. PubMed ID: 25044797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.